F-box and leucine-rich repeat 6 promotes gastric cancer progression via the promotion of epithelial-mesenchymal transition

Figure 1 F-box and leucine-rich repeat 6 is highly expressed in gastric cancer samples and gastric cancer cell lines. A and B: Higher expression of F-box and leucine-rich repeat 6 (FBXL6) was found in gastric cancer (GC) samples than the matched normal tissues (based on GSE54129 and TCGA database); C: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis of FBXL6 mRNA expression in 68 pairs of GC patient samples; D: Western blot analysis was performed using an antibody against FBXL6 in 4 pairs of GC patients’ samples; E: Outcomes of immunohistochemical staining was performed using an antibody against FBXL6 and representative photographs of FBXL6 in GC patients. Scale bar: 100 μm; F: Relationship between FBXL6 expression and clinical parameters in GC by logistic analysis; G: RT-qPCR and Western blot analysis show the expression of FBXL6 in different GC cell lines (MKN-45, MGC-803 and HGC-27) and GES-1; H and I: Immunofluorescence staining examine the expression and localization of FBXL6 were using in GC cells (H) and tissues (I); J: Kaplan-Meier plots of overall survival and progression-free survival for GC samples from the K-M Plotter database. ^bP < 0.01; ^cP < 0.001. FBXL6: F-box and leucine-rich repeat 6.